View ValuationMINAPHARM Pharmaceuticals 将来の成長Future 基準チェック /06現在、 MINAPHARM Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長13.5%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egyptお知らせ • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan EgyptNew Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.お知らせ • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、MINAPHARM Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測CASE:MIPH - アナリストの将来予測と過去の財務データ ( )EGP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数9/30/20256,924112-440377N/A6/30/20256,936221-426369N/A3/31/20256,288166-85313N/A12/31/20245,665128-698222N/A9/30/20244,423-127-715160N/A6/30/20243,916-259-694231N/A3/31/20243,904-154-89795N/A12/31/20233,892-55-1,303102N/A9/30/20234,025281-1,376217N/A6/30/20234,003461-1,312330N/A3/31/20233,794529-1,144450N/A12/31/20223,621590-600562N/A9/30/20223,442544-443429N/A6/30/20223,212467-334349N/A3/31/20223,032454-79393N/A12/31/20213,005448-182207N/A9/30/20212,9184224281N/A6/30/20212,754398235442N/A3/31/20212,583325170359N/A12/31/20202,361285284437N/A9/30/20202,200271305487N/A6/30/20202,115216225417N/A3/31/20202,080174188381N/A12/31/20192,051141-39206N/A9/30/20191,91786-106156N/A6/30/20191,93667N/A104N/A3/31/20191,94881N/A269N/A12/31/20181,919116N/A334N/A9/30/20181,928156N/A240N/A6/30/20181,820186N/A107N/A3/31/20181,717198N/A-8N/A12/31/20171,646175N/A-4N/A9/30/20171,49365N/A267N/A6/30/20171,32555N/A316N/A3/31/20171,19035N/A355N/A12/31/20161,03533N/A436N/A9/30/20161,02386N/A188N/A6/30/20161,01997N/A258N/A3/31/20161,001110N/A238N/A12/31/201596683N/A161N/A9/30/201591685N/A147N/A6/30/201588561N/A102N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: MIPHの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: MIPHの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: MIPHの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: MIPHの収益がEG市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: MIPHの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: MIPHの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/09 19:18終値2026/06/09 00:00収益2025/09/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋MINAPHARM Pharmaceuticals 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • May 06MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 02, 2026, at 15:00 Egypt Standard Time. Location: cairo Egypt
お知らせ • May 27MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025MINAPHARM Pharmaceuticals, Annual General Meeting, Jun 18, 2025, at 15:00 Egypt Standard Time. Location: tenth of ramadan Egypt
New Risk • May 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.7x net interest cover). Earnings have declined by 13% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.6% average weekly change). Market cap is less than US$100m (ج.م2.34b market cap, or US$46.7m).
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
New Risk • Sep 11New major risk - Revenue and earnings growthEarnings have declined by 2.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings have declined by 2.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (ج.م1.83b market cap, or US$37.8m).
Reported Earnings • Jun 04First quarter 2024 earnings released: EPS: ج.م0.37 (vs ج.م3.49 in 1Q 2023)First quarter 2024 results: EPS: ج.م0.37 (down from ج.م3.49 in 1Q 2023). Revenue: ج.م984.3m (up 1.2% from 1Q 2023). Net income: ج.م4.05m (down 90% from 1Q 2023). Profit margin: 0.4% (down from 4.0% in 1Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has increased by 31% per year, which means it is well ahead of earnings.
New Risk • Mar 16New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (11% operating cash flow to total debt). High level of non-cash earnings (47% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (ج.م2.88b market cap, or US$60.2m).
Valuation Update With 7 Day Price Move • Jan 25Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م249, the stock trades at a trailing P/E ratio of 6x. Average trailing P/E is 8x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 219% over the past three years.
Valuation Update With 7 Day Price Move • Nov 21Investor sentiment improves as stock rises 17%After last week's 17% share price gain to ج.م238, the stock trades at a trailing P/E ratio of 5.7x. Average trailing P/E is 7x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 223% over the past three years.
Reported Earnings • Aug 31Second quarter 2023 earnings released: EPS: ج.م7.92 (vs ج.م11.31 in 2Q 2022)Second quarter 2023 results: EPS: ج.م7.92 (down from ج.م11.31 in 2Q 2022). Revenue: ج.م1.07b (up 24% from 2Q 2022). Net income: ج.م87.7m (down 35% from 2Q 2022). Profit margin: 8.2% (down from 16% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth.
Upcoming Dividend • Jun 29Upcoming dividend of ج.م2.80 per share at 1.3% yieldEligible shareholders must have bought the stock before 06 July 2023. Payment date: 10 July 2023. Payout ratio is a comfortable 6.2% but the company is not cash flow positive. Trailing yield: 1.3%. Lower than top quartile of Egyptian dividend payers (7.5%). Lower than average of industry peers (3.5%).
Reported Earnings • Jun 01First quarter 2023 earnings released: EPS: ج.م3.86 (vs ج.م10.24 in 1Q 2022)First quarter 2023 results: EPS: ج.م3.86 (down from ج.م10.24 in 1Q 2022). Revenue: ج.م972.2m (up 22% from 1Q 2022). Net income: ج.م49.9m (down 60% from 1Q 2022). Profit margin: 5.1% (down from 16% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 46% per year, which means it is tracking significantly ahead of earnings growth.
Valuation Update With 7 Day Price Move • May 22Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ج.م227, the stock trades at a trailing P/E ratio of 4.3x. Average trailing P/E is 4x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 261% over the past three years.
Reported Earnings • Dec 04Third quarter 2022 earnings released: EPS: ج.م17.41 (vs ج.م8.40 in 3Q 2021)Third quarter 2022 results: EPS: ج.م17.41 (up from ج.م8.40 in 3Q 2021). Revenue: ج.م984.6m (up 30% from 3Q 2021). Net income: ج.م184.0m (up 80% from 3Q 2021). Profit margin: 19% (up from 14% in 3Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 52% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jul 20Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م164, the stock trades at a trailing P/E ratio of 4.4x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 118% over the past three years.
Upcoming Dividend • Jun 20Upcoming dividend of ج.م2.92 per shareEligible shareholders must have bought the stock before 27 June 2022. Payment date: 29 June 2022. Payout ratio is a comfortable 7.8% but the company is not cash flow positive. Trailing yield: 1.9%. Lower than top quartile of Egyptian dividend payers (11%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • May 31Investor sentiment improved over the past weekAfter last week's 15% share price gain to ج.م150, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 95% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. No highly experienced directors. No independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Jan 10Investor sentiment improved over the past weekAfter last week's 18% share price gain to ج.م128, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 75% over the past three years.
Upcoming Dividend • May 19Upcoming dividend of ج.م2.70 per shareEligible shareholders must have bought the stock before 26 May 2021. Payment date: 30 May 2021. Trailing yield: 2.5%. Lower than top quartile of Egyptian dividend payers (8.2%). Lower than average of industry peers (4.2%).
Valuation Update With 7 Day Price Move • Apr 28Investor sentiment improved over the past weekAfter last week's 16% share price gain to ج.م99.28, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 18% over the past three years.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ج.م84.88, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 1.0% over the past three years.
Reported Earnings • Apr 04Full year 2020 earnings releasedThe company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: ج.م2.36b (up 15% from FY 2019). Net income: ج.م300.8m (up 113% from FY 2019). Profit margin: 13% (up from 6.9% in FY 2019). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Feb 08Investor sentiment improved over the past weekAfter last week's 34% share price gain to ج.م111, the stock is trading at a trailing P/E ratio of 5x, up from the previous P/E ratio of 3.7x. This compares to an average P/E of 6x in the Pharmaceuticals industry in Egypt. Total returns to shareholders over the past three years are 68%.
Is New 90 Day High Low • Feb 03New 90-day high: ج.م86.57The company is up 15% from its price of ج.م75.13 on 05 November 2020. The Egyptian market is also up 15% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Jan 12New 90-day high: ج.م85.89The company is up 15% from its price of ج.م75.00 on 14 October 2020. The Egyptian market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is flat over the same period.
Reported Earnings • Dec 04Third quarter 2020 earnings released: EPS ج.م6.32The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2020 results: Revenue: ج.م590.8m (up 17% from 3Q 2019). Net income: ج.م77.6m (up 247% from 3Q 2019). Profit margin: 13% (up from 4.4% in 3Q 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth.
Is New 90 Day High Low • Nov 30New 90-day high: ج.م80.50The company is up 4.0% from its price of ج.م77.15 on 01 September 2020. The Egyptian market is up 2.0% over the last 90 days, indicating the company outperformed over that time. However, its price trend is similar to the Pharmaceuticals industry, which is also up 4.0% over the same period.
お知らせ • Jul 31Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million.Shaheer Wafik Saad El Bardisy acquired an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) for approximately EGP 100 million on July 26, 2020. Shaheer Wafik Saad El Bardisy bought 1.2 million shares and increased his stake to 10.89%. Shaheer Wafik Saad El Bardisy completed the acquisition of an additional 10% stake in MINAPHARM Pharmaceuticals (CASE:MIPH) on July 26, 2020.